Investor Roadshow Presentation - September 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Preliminary Final Report
- Receipt of GMP Grade Tablets for Phase II Trials
- Response to ASX Price and Volume Query
- PharmAust receives ethics approval to begin Phase II Trial
- Epichem Final Loan Repayment Milestone for New Laboratory
Later from Neurizon Therapeutics
- Phase II Dog Cancer Trial Commences
- Agreement with Uni of Melbourne U-Vet for Phase II Dog Trial
- PharmAust Raises $2.4m in Placement
- Epichem Export Business Receives Important WA State Awards
- PharmAust Receives Pre-Approval for R&D Tax Rebates
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics